Pfizer agreed to lower drug costs and invest $70 billion in U.S. manufacturing following a deal with the Trump administration. The drugmaker will implement "most-favored-nation" pricing for Medicaid and new drugs, matching international low prices. This move supports Trump's long-standing effort to reduce drug expenses and boost domestic production.
Pfizer agrees to lower prescription drug costs for Medicaid in a deal with Trump
